Table 6

Causes of death

Treated patients, n (%)
Dasatinib, N = 258Imatinib, N = 258
Total deaths 16 (6) 14 (5) 
Death on study treatment or within 30 days of last dose 7 (3) 4 (2) 
Death > 30 days after discontinuing study treatment 9 (3) 10 (3) 
Causes of death   
    CML progression 8 (3) 10 (4) 
    Cardiovascular disease 2 (1) 1 (< 1) 
    Infection 5 (2) 1 (< 1) 
    Bleeding 1 (< 1) 
    Other neoplasm 1 (< 1) 
    Clinical deterioration* 1 (< 1) 
Treated patients, n (%)
Dasatinib, N = 258Imatinib, N = 258
Total deaths 16 (6) 14 (5) 
Death on study treatment or within 30 days of last dose 7 (3) 4 (2) 
Death > 30 days after discontinuing study treatment 9 (3) 10 (3) 
Causes of death   
    CML progression 8 (3) 10 (4) 
    Cardiovascular disease 2 (1) 1 (< 1) 
    Infection 5 (2) 1 (< 1) 
    Bleeding 1 (< 1) 
    Other neoplasm 1 (< 1) 
    Clinical deterioration* 1 (< 1) 
*

The patient who died after clinical deterioration while receiving imatinib therapy had progressive severe grade 4 peripheral edema despite diuretics, with acute renal failure and rapid decline in performance status ultimately leading to cardiorespiratory arrest. The leading cause of death was unknown.

or Create an Account

Close Modal
Close Modal